Noticias y Actividades de Surrozen

Surrozen es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Ver el organigrama con sus 24 ejecutivos principales

Biografías más buscadas en Surrozen

• Craig Parker, Chief Executive Officer and Director
• Mary Haak-Frendscho, Director
• Anna Berkenblit, Director

Recientes movimientos de ejecutivos en Surrozen

• Andrew Maleki se incorporará a la empresa como Chief Financial Officer el 12 de nov.. de 2025  (noticia publicada el 10 de noviembre de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en Surrozen.

Surrozen tiene 2.428 competidores entre los que se incluyen Lonza (Suiza), Vertex Pharmaceuticals (Estados Unidos) y Eurofins (Luxemburgo).

Popular M&A news in Biotecnología

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado el 17 de julio de 2026).
• GSK ha Nuvalent adquirido (publicado el 17 de julio de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado el 15 de julio de 2026).

Otros contactos sugeridos en el sector Biotecnología

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer en Inceptive
• Jan Van de Winkel - President and Chief Executive Officer en Genmab
• Robert Gould - Board Member en Fulcrum Therapeutics

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Surrozen

• Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis | Surrozen
• Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) | Surrozen
• Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis | Surrozen
• Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise
• Surrozen Reports First Quarter 2022 Financial Results | Surrozen
• Surrozen to Present at the BofA Securities 2022 Healthcare Conference | Surrozen
• Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting | Surrozen
• Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results | Surrozen
• Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline | Surrozen
• Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference | Surrozen
• View more press releases Close

Redes sociales sobre Surrozen

• Surrozen en Wikipedia, Google News y Yahoo Finance
• Surrozen en LinkedIn, Twitter y YouTube